Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

25.0%

1 terminated/withdrawn out of 4 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

N/A
2(66.7%)
Phase 4
1(33.3%)
3Total
N/A(2)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03729713Not ApplicableUnknown

Computerized Cognitive Rehabilitation in MS Patients

Role: collaborator

NCT02846779Not ApplicableCompleted

Targeted Adherence Intervention to Reach Glycemic Control With Insulin Therapy for Patients With Diabetes

Role: collaborator

NCT02671045Terminated

Genomic Profiling in Previously Untreated Metastatic Non-small Cell Lung Cancer

Role: collaborator

NCT03328052Phase 4Unknown

MYnd Analytics Directed Therapy in Depression

Role: collaborator

All 4 trials loaded